{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:39:09Z","timestamp":1784900349438,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R03CA259489"],"award-info":[{"award-number":["R03CA259489"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chimeric antigen receptor-T (CAR-T) cell therapy has improved survival, yet its toxic profile may impact on survivors\u2019 well-being. We examined patients\u2019 and caregivers\u2019 perspectives on the most common, severe, and distressing side effects across recovery (ie, first 60\u2009days) and survivorship (ie, 60\u2009days and onwards) and explored their perspectives on the education received to prepare for CAR-T.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We conducted semi-structured interviews with patients and caregivers addressing (1) how they prepared for CAR-T, (2) the side effects experienced during the first-year post-treatment, and (3) how to best educate future patients and caregivers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 19 patients and 12 caregivers. We identified 6 major themes. First, participants reported intense hope as well as stress and fear when presented with CAR-T, viewing it as a distinct and exceptional treatment. Second, following CAR-T infusion, some patients experienced intense symptoms (eg, fatigue, pain), while others were confused if not presenting with symptoms. Third, following discharge, patients experienced a myriad of ongoing symptoms, some of which were severe (eg, fatigue, cognitive symptoms, pain) and negatively impacted on their recovery. Fourth, some long-term survivors experienced ongoing symptoms but accepted this trade-off for being alive. Fifth, most patients and caregivers felt well prepared to cope with CAR-T, although some expressed the desire for more information on long-term side effects. Sixth, participants would recommend CAR-T to others while acknowledging the risk of experiencing side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Participants commonly reported significant symptoms throughout treatment and recovery. Additional education on long-term survivorship is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf246","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:16:08Z","timestamp":1755018968000},"source":"Crossref","is-referenced-by-count":1,"title":["Patients\u2019 and caregivers\u2019 perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-5920","authenticated-orcid":false,"given":"Anna","family":"Barata","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermioni L","family":"Amonoo","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital , Boston, MA 02115,","place":["United States"]},{"name":"Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Traeger","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-3280","authenticated-orcid":false,"given":"Ashley M","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Connor","family":"Johnson","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini M","family":"Dhwale","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Karpinski","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S L","family":"Jim","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior at the Moffitt Cancer Center , Tampa, FL 33612,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025100319570526900_oyaf246-B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long-term survivorship care after CAR-T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"key":"2025100319570526900_oyaf246-B2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100319570526900_oyaf246-B3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025100319570526900_oyaf246-B4","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"key":"2025100319570526900_oyaf246-B5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"key":"2025100319570526900_oyaf246-B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194711","article-title":"Patient-reported outcomes among multiple myeloma patients treated with standard of care idecabtagene vicleucel","volume":"15","author":"Oswald","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100319570526900_oyaf246-B7","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"key":"2025100319570526900_oyaf246-B8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025100319570526900_oyaf246-B9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025100319570526900_oyaf246-B10","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"key":"2025100319570526900_oyaf246-B11","doi-asserted-by":"publisher","first-page":"401.e1","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients\u2019 perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025100319570526900_oyaf246-B12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100319570526900_oyaf246-B13","doi-asserted-by":"publisher","first-page":"106921","DOI":"10.1016\/j.leukres.2022.106921","article-title":"Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial","volume":"120","author":"Shah","year":"2022","journal-title":"Leuk Res"},{"key":"2025100319570526900_oyaf246-B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clml.2022.10.001","article-title":"Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed\/refractory multiple myeloma in the CARTITUDE-1 study","volume":"23","author":"Cohen","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100319570526900_oyaf246-B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with CAR T-cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"key":"2025100319570526900_oyaf246-B16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00520-024-08799-3","article-title":"Promoting patient-centered care in CAR-T therapy for hematologic malignancy: a qualitative meta-synthesis","volume":"32","author":"Xie","year":"2024","journal-title":"Support Care Cancer"},{"key":"2025100319570526900_oyaf246-B17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"2025100319570526900_oyaf246-B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100319570526900_oyaf246-B19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"2025100319570526900_oyaf246-B20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bmt.2014.118","article-title":"Caregivers\u2019 quality of life after blood and marrow transplantation: a qualitative study","volume":"49","author":"Jim","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2025100319570526900_oyaf246-B21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bmt.2013.158","article-title":"Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life","volume":"49","author":"Jim","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2025100319570526900_oyaf246-B22","author":"Columbia University Irving Medical School. Content Analysis","year":"2025"},{"key":"2025100319570526900_oyaf246-B23","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Qual Quant"},{"key":"2025100319570526900_oyaf246-B24","doi-asserted-by":"publisher","first-page":"402.e1","DOI":"10.1016\/j.jtct.2024.01.069","article-title":"Communication about chimeric antigen receptor T-cell (CAR-T) therapy","volume":"30","author":"Dhawale","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100319570526900_oyaf246-B25","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/cncr.32808","article-title":"Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes","volume":"126","author":"Cusatis","year":"2020","journal-title":"Cancer"},{"key":"2025100319570526900_oyaf246-B26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.70011","article-title":"Pilot randomized controlled trial of an educational video for CAR T-cell therapy recipients","volume":"22","author":"Johnson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100319570526900_oyaf246-B27","author":"Center for International Blood and Marrow Transplat Research"},{"key":"2025100319570526900_oyaf246-B28","author":"Statista"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf246\/63961241\/oyaf246.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf246\/63961241\/oyaf246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf246\/63961241\/oyaf246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:57:11Z","timestamp":1759535831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf246\/8222738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf246","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,5]]},"article-number":"oyaf246"}}